Side effects are uncommon but include stomach pain, nervousness, giddiness, skin rash and leukopenia. It is counter-indicated in breast feeding as it is passed in the milk.
Administration is oral, though it has an unpleasant taste. It is quickly absorbed and elimination is renal and complete within 48 hours. Beclamide is presumably metabolized to 3-chloropropanoic acid in vivo, which binds to the GHB receptor.
It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures. It is no longer used as an AED. Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia.
Wipo Publishes Patent of Grunenthal for "Pharmaceutical Composition Comprising (1R,4r)-6'-Fluoro-N,n-Dimethyl-4-Phenyl-4',9'-Dihydro-3'h-Spiro[cyclohexane-1,1'-Pyrano [3,4,B]indol]-4-Amine and an Anticonvulsant" (German Inventors)
Nov 26, 2013; GENEVA, Nov. 26 -- Publication No. WO/2013/170972 was published on Nov. 21.Title of the invention: "PHARMACEUTICAL COMPOSITION...